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ABSTRACT  
 
Increased adrenocortical secretion of hormones, primarily cortisol in depression, is one 
of the most consistent findings in neuropsychiatry. The maintenance of the internal 
homeostatic state of an individual is facilitated by the ability to circulate glucocorticoids 
to exert negative feedback on the secretion of hypothalamic-pituitary-adrenal (HPA) 
hormones through binding to mineralocorticoid (MR) and glucocorticoid (GR) receptors, 
thus limiting the vulnerability to diseases related to psychological stress in genetically 
predisposed individuals. The HPA axis response to stress can be thought of as a crucial 
part of the organism's response to stress: acute responses are generally adaptive, but 
excessive or prolonged responses can lead to deleterious effects. A spectrum of conditions 
may be associated with increased and prolonged activation of the HPA axis, including 
depression, poorly controlled diabetes mellitus, and metabolic syndrome. HPA axis 
dysregulation and hypercortisolemia may further contribute to a hyperglycaemic or 
poorly controlled diabetic state. 
 
Keywords: hypothalamic–pituitary–adrenal (HPA) axis, cortisol, mineralocorticoid (MR) 
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A. INTRODUCTION 
The relationship between stress and affective(mood) disorders is a strong example of a 
field of study that can be best understood from an integrative perspective. During acute 
stress, adaptive physiological responses occur, including increased adrenocortical 
hormone secretion, primarily cortisol. Whenever an acute interruption of this balance 
occurs, illness may result. Particularly interesting are psychological stress (i.e., stress in 
the mind) interactions with the nervous, endocrine, and immune systems. It is now 
broadly accepted that psychological stress may change the internal homeostatic state of 
an individual [1]. 
During acute stress, adaptive physiological responses occur, which include hyperactivity 
of the hypothalamic–pituitary–adrenal (HPA) axis. Whenever there is an acute 
interruption of this balance, illness may result. The social and physical environments have 
an enormous impact on our physiology and behaviour, and they influence the process of 
adaptation or ‘allostasis'.  It is correct to state that at the same time that our experiences 
change our brain and thoughts, namely, changing our mind, they are also changing our 
neurobiology [2]. 
B. PHYSIOLOGY OF THE HPA AXIS 
The HPA axis constitutes one of the major endocrine systems that maintains 
homoeostasis when the organism is challenged or stressed. Activation of the HPA axis is 
perhaps the most important endocrine component of the stress response [3]. Abnormal 
activation of the HPA axis, as well as increased circulating levels of cortisol, is one 
potential explanation for many of the features of depression, and many previous studies 
have described an impaired HPA negative feedback, leading to hypercortisolemia, in the 
most severe forms of depression [4]. 
Cortisol mediates its action, including feedback regulation of the HPA axis, through two 
distinct intracellular corticosteroid receptor subtypes in the brain: the type-I, high affinity, 
mineralocorticoid receptor (MR) and type-2, glucocorticoid receptor (GR) [5]. The type-
I receptor (MR) has a limited distribution, and it is found in relatively high density in the 
hippocampus and sensory and motor sites outside the hypothalamus. The expression of 
type-II receptors (GR) is more widespread, and they are found in the hippocampus, the 
amygdala, the hypothalamus, and the catecholaminergic cell bodies of the brain stem [6]. 
There is a theory that suggests that a GR defect may mediate the impaired negative 
feedback thought to cause hypercortisolemia in depression [7]. 
Under basal levels of cortisol, negative feedback is mediated mainly through the MR in 
the hippocampus, whereas under stress and high cortisol concentrations, feedback is 
mediated by the less sensitive GR in the hippocampus, hypothalamus, and pituitary gland. 
The balance in these MR- and GR-mediated effects on the stress system is of crucial 
importance to the set point of the HPA axis activity [5].  
It is proposed that the maintenance of corticosteroid homeostasis and the balance in MR-
/GR-mediated effects limit vulnerability to stress-related diseases 
in genetically predisposed individuals. Stress-induced activation of the HPA axis 
generally involves stimulated release of corticotropin-releasing factor (CRF) from the 
paraventricular nucleus (PVN) of the hypothalamus into the portal venous circulation, 
where CRF stimulates the synthesis of proopiomelancortin, the precursor of 
adrenocorticotropic hormone (ACTH) from anterior pituitary cells. Arginine-vasopressin 
(AVP) is a potent synergistic factor with CRF in stimulating ACTH secretion [8]. 
In the hypothalamus, the PVN receives fibers from a number of brain areas, notably the 
brain stem and limbic system (e.g., amygdala and the septal areas). It is thought that these 
afferents may be important in HPA responses to behavioural and emotional stimuli and 
may play a role in corticosteroid feedback. Several peptides are released alongside and 
interact with CRF at the level of the anterior pituitary and alter the stimulatory action of 
ACTH secretion [9] Increases in circulating ACTH stimulate glucocorticoid release from 
the adrenal cortex (see Fig. 1). 
INSERT FIGURE 1 
 
The division of the adrenal cortex into separate layers is important since zones produce 
different steroids [10]. Table 1 summarises the adrenal steroids. Cortisol is produced by 
the zona fasciculata at the rate of 12–15 mg/m2 of body surface area per day. However, 
more than 90% of the circulating cortisol is bound to corticosteroid-binding globulin 
(CBG) in humans and rodents. Also, it has been observed that both exogenous 
glucocorticoid administration and endogenous increases in plasma cortisol (for example, 
Cushing's syndrome) result in a 30–40% decrease in the plasma CBG concentration. 
Thus, CBG levels fluctuate according to glucocorticoid concentration [11-12]. 
INSERT TABLE 1 
 
Adrenocorticotropic hormone is secreted in irregular bursts throughout the day, and 
plasma cortisol tends to rise and fall in response to this pulsatile secretion. In humans, the 
bursts are most frequent in the early morning and least frequent in the evening. The 
biological clock responsible for the diurnal ACTH rhythm is thought to be located in the 
suprachiasmatic nuclei of the hypothalamus. Changes in the activity of these neurones 
increase the release of CRF and AVP by the PVN during usual times of peak activity. 
Consequently, it is thought that the secretion of CRF and AVP also follows a pulsatile 
pattern. However, CRF 
levels in human peripheral plasma are very low and do not exhibit circadian variation, 
and therefore, these levels cannot be used reliably to assess hypothalamic CRF release 
relevant to the HPA axis. An important feature is the intrinsic rhythmicity of the HPA 
axis with regard not only to the diurnal variation but also to the pulsatility, which is 
comparable to the rhythm found within the reproductive and growth hormone axes [10]. 
A wide variation in cortisol levels is observed among individuals in response to a stressor. 
This variability is so marked that in any one individual, it is not always possible to 
distinguish a stress response from a spontaneously occurring pulse. Young and Altemus 
[13] put forward a totally different hypothesis that acute stressors simply “advance” a 
spontaneous cortisol pulse rather than activate cortisol release as an independent variable, 
thereby acting as a synchronizer or “zeitgeber” for the ultradian cortisol rhythm, whose 
effectiveness will depend on a number of variables that control the individual's 
endogenous rhythm.  Finally, pulsatility analysis enables us to examine multiple aspects 
of the control of the HPA axis, extending our understanding well beyond mean cortisol 
levels [13]. 
Glucocorticoids control their own synthesis and release by completing a negative 
feedback loop at the level of the anterior pituitary, hypothalamus, and other higher 
centres, including the mesencephalic reticular formation. The circulating concentration 
of cortisol is a major influence at both the hypothalamic and pituitary levels (see Table 
2). The negative feedback mechanisms constitute a rate-sensitive fast feedback system 
and a delayed feedback system. Fast feedback is proportional to the rate of rising of 
steroid concentrations and perhaps serves to limit the amplitude of the response. In 
contrast, delayed feedback is related to the ambient concentration of corticosteroid and is 
frequently the consequence of repeated or continuous administration of high doses of 
glucocorticoids. Delayed feedback may persist for days or weeks after the steroid 
treatment is withdrawn [9-11]. 
INSERT TABLE 2 
 
B.1. THE GLUCOCORTICOID RECEPTORS 
 
Steroid hormones are small, lipid-soluble ligands that diffuse across cell membranes. 
Unlike the receptors for peptide hormones, which are located in the cell membrane, the 
receptors for these ligands are localised in the cytoplasm. In response to ligand binding, 
steroid hormone receptors translocate to the nucleus, where they regulate the expression 
of certain genes by binding to specific hormone response elements (HREs) in their 
regulatory regions. Type-I receptors are thought to be involved in controlling the basal 
expression of CRF and AVP at the nadir of diurnal ACTH secretion and in controlling 
peak ACTH secretion [14-15]. Type-II receptors are considered to be involved in control 
of stress-induced ACTH secretion. According to the "nucleocytoplasmic traffic" model 
of GR action, the GR in its “unactivated” form resides primarily in the cytoplasm in 
association with a multimeric complex of chaperone proteins including several heat shock 
proteins (HSPs). After being bound by steroid, the GR undergoes a conformational 
change, dissociates from the chaperone protein complex, and translocates from the 
cytoplasm to the nucleus, where it either binds to glucocorticoid response elements 
(GREs) on DNA or interacts with other transcription factors. Glucocorticoid response 
elements can confer either positive or negative regulation of the genes to which they are 
linked. Glucocorticoid receptors have a low affinity but high capacity for cortisol and are 
very responsive to changes in cortisol concentrations [14-15]. 
Studies on the subcellular localisation of the MR have been controversial. In the lack of 
corticosteroid hormone, MR is present both in the cytoplasm and in the nucleus. However, 
the presence of corticosteroid hormone induced a rapid nuclear accumulation of the MR. 
The MR has a high affinity for endogenous glucocorticoids: the in vitro dissociation 
constant/ionisation constant (Kd/Ki) is 0.13nM for cortisol binding to human MR and 0.5 
nM for corticosterone binding to mouse MR. In contrast, the GR has a low affinity for 
endogenous glucocorticoids: the in vitro Kd/Ki is 15 nM for cortisol binding to human 
GR and 5 nM for corticosterone binding to mouse GR. Under basal levels of cortisol, 
negative feedback is mediated mainly through the MR in the hippocampus, whereas under 
stress and high cortisol concentrations, the less sensitive GR in the hippocampus, 
hypothalamus, and pituitary gland come into play. The balance in these MR- and GR-
mediated effects on the stress system is of crucial importance to the set point of the HPA 
axis activity [16]. Spencer et al. [14] and de Kloet et al. [5] have clarified that GR 
activation is necessary for the HPA feedback regulation when levels of glucocorticoids 
are high (response to stress, circadian peak) but that MR also plays an important role by 
modulating GR-dependent regulation. 
 
B.2. BRAIN CORTICOSTEROID BALANCE IN HEALTH AND DISEASE 
 
Data on corticosteroid receptor diversity led de Kloet et al. [5] to a working hypothesis 
that in rodents, “tonic influences of corticosterone are exerted via hippocampal MRs, 
while the additional occupancy of GRs with higher levels of corticosterone mediates 
feedback actions aimed to restore disturbances in homeostasis”. This proposal provides a 
receptor-based version of Selye's classical “pendulum hypothesis” on opposing effects of 
mineralocorticoids and glucocorticoids in host defense. In humans, while MRs are 
thought to be involved in the tonic inhibitory activity within the HPA axis, GRs appear 
to “switch off” cortisol production at times of stress [17]. According to Pace and Spencer 
[18], MRs may be necessary for glucocorticoid regulation of HPA axis activity during 
mild stressors but not during stressors that result in a stronger corticosterone response. It 
is proposed that the maintenance of corticosteroid homeostasis and the balance in 
MR/GR-mediated effects limit vulnerability to stress-related diseases in genetically 
predisposed individuals [5]. 
 
 
 
B.3. STATES ASSOCIATED WITH HYPERACTIVATION  
 
Hyperactivity of the HPA axis in depression is one of the most consistent findings in 
psychiatry. A significant percentage of patients with major depression have been shown 
to exhibit increased concentrations of cortisol in plasma, urine, and cerebrospinal fluid 
(CSF); an exaggerated cortisol response to adrenocorticotropic hormone (ACTH); and an 
enlargement of both the pituitary and adrenal glands [4]. Adrenal hypertrophy in patients 
with depression has been demonstrated, and this finding likely explains why the cortisol 
response to CRF is similar in subjects with depression and control subjects because the 
enlarged adrenal gland is capable of compensating for the blunted ACTH response to 
CRF commonly observed in patients with depression [16]. Increased pituitary volume in 
these patients has also been described, and it has also been considered a marker of HPA 
axis activation. The first episode of a psychosis has also been found to be associated with 
a larger pituitary volume, and it has been suggested that this is due to activation of the 
HPA axis; the smaller pituitary volume in subjects with established psychosis could also 
be the consequence of repeated episodes of HPA axis hyperactivity. In general, HPA axis 
changes appear to be state-dependent, tending to improve upon resolution of the 
depressive syndrome. In fact, previous studies have described an impaired HPA negative 
feedback, leading to hypercortisolemia [16-19]. 
A spectrum of other conditions may be associated with increased and prolonged 
activation of the HPA axis, including anorexia nervosa with or without malnutrition, 
obsessive–compulsive disorder, panic anxiety, chronic active alcoholism, alcohol and 
narcotic withdrawal, poorly controlled diabetes mellitus, and hyperthyroidism [20]. 
Another group of states is characterised by hypoactivation of the stress system, rather 
than sustained activation, in which chronically reduced secretion of CRF may result in 
pathological hypoarousal and an enhanced HPA negative feedback. Patients with 
posttraumatic stress disorder, atypical depression, seasonal depression, and chronic 
fatigue syndrome fall into this category [21], see figure 2. 
INSERT FIGURE 2 
 
The dysregulations situate themselves at different levels of the HPA axis, and the 
experimental findings can be classified under basal hormonal changes, postmortem 
findings, and results from imaging studies and functional tests. Theories as to the causes 
of abnormal HPA axis function in depression are that it is related to either (a) increased 
central drive at the hypothalamic level or (b) downregulation of GRs. Taking the first 
theory, it has been suggested that hypercortisolism represents a defect at or above the 
level of the hypothalamus, resulting in the hypersecretion of CRF and AVP [4]. 
Corticotropin-releasing factor itself has behavioural effects in animals that are similar to 
those seen in patients with depression including alterations in activity, appetite, and sleep 
[21]. The second theory suggests that a defect of GRs may also explain the 
hypercortisolemia seen in depression, via impaired negative feedback control of the HPA 
axis by glucocorticoids. Various research groups have suggested that the overactivity of 
the HPA axis in depression may be due to an abnormality of the GR at the limbic–
hippocampal level [7-10]. This abnormality then results in a defect in or resistance to 
glucocorticoid. In fact, several findings in depression are consistent with an abnormality 
of the GR. Most notably, patients with depression fail to show most of the physical 
symptoms of corticosteroid excess, despite the frequent presence of hypercortisolism, 
suggesting that peripheral GRs may be abnormal or insensitive in depression. Consistent 
with the fact that GR is more important in the regulation of the HPA axis when 
endogenous levels of glucocorticoids are high [5] and with the fact that patients with 
major depression exhibit impaired HPA negative feedback in the context of elevated 
circulating levels of cortisol [16], a number of studies have described reduced GR 
function in patients with depression (GR resistance) and have concluded that 
antidepressants act by reversing these putative GR changes [16,22-23]. 
Because a wide variety of stressors reliably activate the HPA axis and because 
glucocorticoids are the end-products of HPA axis activation, these hormones have been 
most commonly seen as the agents provocateurs, or even in extreme cases as the physical 
embodiment, of stress-induced pathology [16,22-23]. Indeed, it has been suggested that 
prolonged overproduction of glucocorticoids, whether as a result of ongoing stress or a 
genetic predisposition to HPA axis hyperactivity, damages brain structures (especially 
the hippocampus) essential for HPA axis restraint. Such damage, in turn, has been 
hypothesised to lead to a feed-forward circuit in which ongoing stressors drive 
glucocorticoid overproduction indefinitely: the “glucocorticoid cascade hypothesis”. 
Because of the capacity of high concentrations of glucocorticoids to disrupt cellular 
functioning in ways that can lead to a host of ills, this glucocorticoid overproduction is 
believed to contribute directly to many of the adverse behavioural and physiological 
sequelae associated with chronic stress [24-25]. 
 
B.4. ASSESSING THE IMPAIRED HPA NEGATIVE FEEDBACK 
Functioning of the HPA axis can be assessed under basal as well as under challenged 
conditions. Basal cortisol mainly reflects adrenal functioning, whereas several challenge 
paradigms target different levels of the HPA axis [6-11]. Cortisol is secreted with a 
pulsatory diurnal rhythm, with a peak (average increase of 50%) approximately 30min 
after awakening and a progressive decline during the day with lowest levels around 
midnight. Basal cortisol may be assessed in several bodily fluids such as saliva, urine, 
blood (serum or plasma), and cerebrospinal fluid. Whereas salivary free cortisol and 
urinary free cortisol consist almost entirely of the (free) biologically active fraction, in 
blood, less than 10% of the cortisol is free. The major part is bound to cortisol-binding 
globulin or other 
proteins and, therefore, biologically inactive. A distinction can be made between 
psychosocial stress challenges and pharmacological stress challenges. Examples of the 
psychosocial stress challenges are cognitive stress challenges, challenges using trauma 
related acoustic stimuli, or trauma scripts. The most often used psychosocial stress 
challenge is the Trier Social Stress Test (TSST) that combines social-evaluative threat 
and uncontrollability [26].  
The dexamethasone suppression test (DST) was the first and is, to date, the most studied 
biological marker in research on depressive disorders. In 1968, Bernard Carroll and 
colleagues showed that patients with depression fail to suppress plasma cortisol to the 
same extent as controls without depression. This impaired feedback inhibition by 
dexamethasone has been demonstrated in patients with depression by a variety of studies, 
many occurring in the 1970s and the 1980s. However, in the 1990s, several studies found 
that the sensitivity of the DST in the diagnosis of the DSM-III defined the melancholic 
subclass of major depression was only approximately 35–45%, although the specificity 
was higher at approximately 70–89% [27-28]. A meta-analysis to determine the 
significance of differences in rates of no suppression of cortisol indicated a high 
probability that a greater rate of cortisol no suppression occurs in psychotic depression 
(64% versus 41% in patients without psychosis). The DST/CRH combines the DST and 
the CRH stimulation test in the dexamethasone suppression/corticotropin-releasing 
hormone stimulation (DEX/CRH) test [27-28]. Watson et al. [29] compared the use of 
the DEX/CRH test and the DST in patients with mood disorders and controls, and 
suggested that the two tests measure common pathology but that the DEX/CRH test is 
more specific and hence has better diagnostic utility. Nevertheless, the DEX/CRH test 
remains limited by the pharmacokinetic profile of dexamethasone and the lack of MR 
activity. 
Prednisolone is a synthetic glucocorticoid that, like dexamethasone, is widely used as an 
anti-inflammatory and immunosuppressive drug. Prednisolone mimics cortisol in many 
ways. Like cortisol, it binds to CBG, and its half-life is similar to that of cortisol. 
However, the most important of these similarities is that prednisolone and cortisol are 
similar in their abilities to bind and activate the GR and the MR [17,30-32] 
 
C- HPA AXIS IN DEPRESSION AND IMPLICATIONS FOR DIABETES 
 
Once cortisol is released from the adrenal cortex in response to ACTH stimulation, it 
functions to increase blood glucose levels through its action on glycogen, protein, and 
lipid metabolism. In the liver, cortisol stimulates gluconeogenesis and, in adipose tissue, 
activates lipolysis and free fatty acids (FFA) to be released into the circulation. Cortisol 
also has a permissive effect on glucagon and catecholamine action, thereby contributing 
to insulin resistance and increased blood glucose levels at the expense of glycogen, 
protein, and lipid storage [33-34] 
 
There is growing evidence that depression may cause major life-threatening and disabling 
diseases, such as diabetes mellitus [33]. The metabolic syndrome is a clustering of risk 
factors associated with a particularly high risk of cardiovascular events and diabetes.  
Dysregulation of the HPA-axis is typically associated with chronic stress, and some 
studies have described an association between depression and high cortisol levels  and, in 
turn, elevated levels of cortisol have been related to metabolic syndrome components 
such as abdominal obesity and glucose intolerance [34] 
There is now evidence that insulin exerts important functions in neural development and 
synaptic plasticity[35].These findings have led to the hypothesis that insulin insufficiency 
may lead to the defects in neurocognition commonly observed in depression. Disrupted 
control of adrenocorticotropic hormone (ACTH) release from pituitary corticotrophs and 
direct stimulation of corticotropin-releasing hormone of the adrenal gland with or without 
the release of ACTH leads to hyperactivation of the HPA in patients with diabetes. 
Furthermore, the impairment of glucocorticoid negative feedback sensitivity in patients 
with diabetes also results in increased activity of the HPA axis: following glucocorticoid 
administration, these patients exhibit a greater incidence of no suppression of pituitary–
adrenal activity compared with non-diabetic individuals[36]. Corticosteroids have been 
demonstrated to exert a tonic inhibitory control of hippocampal 5-HT1A receptors; this 
finding is of particular salience given the serotonin deficiency that occurs in depression. 
Once established, the HPA axis dysregulation and hypercortisolemia may further 
contribute to a hyperglycemic or poorly controlled diabetic state and has been associated 
with increased chronic complications of diabetes in adult studies [37] 
 
There are two possible mechanisms underlying the association between Type 2 diabetes 
and the onset of depression. First, biochemical changes associated with diabetes could 
account for the increased risk of depression [38] For example, hyperglycemia and 
hyperinsulinemia increase the activity of the hypothalamic-pituitary-adrenal axis, 
inducing arousal of the nervous system, which in turn may promote depression [39]. 
Second, depression in patients with diabetes may be viewed as the result of the burden of 
the disease. This is supported by the finding that when the burden of diabetes increases, 
the probability of mood symptoms increases as well [40] 
 
Patients with present diabetes alterations of the HPA axis negative feedback [41] 
suggestive of an impairment of corticosteroid receptor sensitivity. HPA axis disturbance 
seems to be particularly important for people with diabetes since the degree of cortisol 
secretion is related to the presence and number of diabetes complications[42]   
At baseline, diabetes patients had increased glucocorticoid, but normal mineralocorticoid 
sensitivity in the presence of hypercortisolemia. The action of dexamethasone—–which 
exclusively binds to GR — and of prednisolone—–which binds to both GR and MR — 
is respectively a proxy for glucocorticoid and mineralocorticoid sensitivity [17, 32] Such 
disturbance in the regulation of the HPA axis may contribute to deterioration in diabetes 
by enhancing the effect of cortisol and its anti-insulin actions, including the inhibition of 
glucose uptake in adipocytes and fibroblasts, increasing hepatic gluconeogenesis, 
sensitizing the liver to catecholamines and glucagon, and elevating blood glucose [43]. 
Our review suggests that in diabetes the ability to match the body’s response to a stressor 
involves modulation of corticosteroid receptor sensitivity, an evidence of insufficient 
corticosteroid signalling. Moreover, insufficient corticosteroid signalling may also 
increase arousal and thus play a role in stress-related pathology.  
 
D- CONCLUSION 
 
Diabetes is associated with a lack of stress-induced modulation of glucocorticoid and 
mineralocorticoid sensitivity in the HPA axis. Emphasis on modulating glucocorticoids 
in stress-related pathology encourages the development of therapeutic strategies to 
modulate glucocorticoid-signalling pathways. 
In conclusion, our review suggests a synergistic relationship between depression, cortisol, 
and diabetes. Persons with hypercortisolemic depression, in particular, may be at risk for 
having the metabolic syndrome, and therefore have an increased risk of developing 
diabetes. 
 
 
References:  
 
[1] Young AH. Cortisol in mood disorders. Stress. 2004 Dec;7(4):205-8.  
[2] Juruena MF Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav. 
2014 Sep;38:148-59  
[3] Nemeroff CB, Evans DL. Correlation between the dexamethasone suppression test in depressed 
patients and clinical response. Am J Psychiatry 1984;141(2):247–9. 
[4] Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. 
Relation to the neurobiology of stress (2).NEngl JMed 1988;319(7):413–20. 
[5] de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and 
disease. Endocr Rev 1998;19(3):269–301. 
[6] McEwen BS.Allostasis and allostatic load: implications for neuropsychopharmacology. 
Neuropsychopharmacology 2000;22(2):108–24. 
 [7] Modell S, Yassouridis A, Huber J, Holsboer F. Corticosteroid receptor function is decreased in 
depressed patients. Neuroendocrinology 1997;65(3):216–22. 
[8] Juruena MF, Cleare AJ, Bauer ME, Pariante CM. Molecular mechanisms of glucocorticoid receptor 
sensitivity and relevance to affective disorders. Acta Neuropsychiatr 2003;15(6):354-67. 
[9] Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocorticoid 
receptor function and relevance to depression. Rev Bras Psiquiatr 2004;26(3):189–201. 
[10] Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL, et al. Do 
corticosteroids damage the brain? J Neuroendocrinol 2006;18:393–411. 
[11] Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N Engl 
J Med 1995;332:1351–62. 
[12] Frairia R, Agrimonti F, FortunatiN, Fazzari A,Gennari P, Berta L. Influence of naturally occurring 
and synthetic glucocorticoids on corticosteroid-binding globulin-steroid interaction in human peripheral 
plasma. Ann N Y Acad Sci 1988;538:287–303. 
[13] Young EA, Altemus M. Puberty, ovarian steroids, and stress. Ann N Y Acad Sci 2004;1021:124–33. 
[14] Spencer RL, Kim PJ, Kalman BA, Cole MA. Evidence for mineralocorticoid receptor facilitation of 
glucocorticoid receptor-dependent regulation of HPA axis activity. Endocrinology 1998;139:2718–26. 
[15] Fejes-Toth G, Pearce D, Naray-Fejes-Toth A. Subcellular localization of mineralocorticoid receptors 
in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci U S A 1998;95:2973–8. 
[16] de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev 
Neurosci 2005;6:463–75. 
[17] Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. Prednisolone 
suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment 
resistance. Br J Psychiatry 2009; 194(4): 342-9. 
[18] Pace TW, Spencer RL. Disruption of mineralocorticoid receptor function increasescorticosterone 
responding to a mild, but not moderate, psychological stressor. Am J Physiol Endocrinol Metab 
2005;288:E1082–8. 
[19] Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 
23: 477–501. 
[20] Tsigos C, Chrousos GP. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J 
Psychosom Res 2002;53:865–71. 
[21] Juruena MF, Cleare AJ. Overlap between atypical depression, seasonal affective disorder and 
chronic fatigue syndrome. Rev Bras Psiquiatr 2007;29:20–7. 
[22] Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic–pituitary–adrenal axis 
function in patients with bipolar disorder. Br J Psychiatry 2004;184:496–502. 
[23] McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. 
Br J Psychiatry 2000;177:390–5. 
[24] Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen 
Psychiatry 2000;57:925–35. 
[25] McEwen BS, Seeman T. Protective and damaging effects of mediators of stress. Elaborating and 
testing the concepts of allostasis and allostatic load. Ann N Y Acad Sci 1999(896):30–47. 
[26] de Kloet CS, Vermetten E, Geuze E, Kavelaars A, Heijnen CJ, Westenberg HGM. Assessment of 
HPA-axis function in posttraumatic stress disorder: pharmacological 
[27] Ribeiro SC, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of outcome in depression: a 
meta-analysis. Am J Psychiatry 1993;150(11):1618–29. 
[28] Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997; 
154(11):1497–503. 
[29] Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH. The dex/CRH test—is it better than the 
DST? Psychoneuroendocrinology 2006;31(7):889–94. 
[30] Pariante CM, Papadopoulos AS, Poon L, Checkley SA, English J, Kerwin RW, et al. A novel 
prednisolone suppression test for the hypothalamic–pituitary–adrenal axis. Biol Psychiatry 
2002;51(11):922–30. 
[31] Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM. Different responses to 
dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl) 
2006;189(2):225–35. 
[32] Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. The role of 
mineralocorticoid receptor function in treatment-resistant depression. J Psychopharmacol 2013 
[33] Brown, L.C., Majumdar, S.R., Newman, S.C., Johnson, J.A., 2005. History of depression increases 
risk of type 2 diabetes in younger adults. Diabetes Care 28, 1063–1067. 
[34] Bjorntorp, P., Rosmond, R., 1999. Hypothalamic origin of the metabolic syndrome X. Ann. N.Y. Acad. 
Sci. 892, 297–307 
[35] Huang CC, Lee CC, Hsu KS (2010) The role of insulin receptor signaling in synaptic plasticity and 
cognitive function. Chang Gung Med J 33:115–125 
[36] Hudson JI, Hudson MS, Rothschild AJ, Vignati L, Schatzberg AF, Melby JC (1984) Abnormal 
results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch Gen 
Psychiatry 41:1086–1089 
[37]Chiodini I, Adda G, Scillitani A et al (2007) Cortisol secretion in patients with type 2 diabetes: 
relationship with chronic complications. Diabetes Care 30:83–88 
[38] Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there 
a link? Diabetes Care 2000;23:1556–62. 
[39]  Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG. Diabetes and the hypothalamo-pituitary-
adrenal (HPA) axis. Minerva Endocrinol 2003;28:87–102. 
[40] Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 
2: epidemiology, biology, and treatment. Biol Psychiatry 2003;54:317–29. 
[41] Bruehl, H., Rueger, M., Dziobek, I., Sweat, V., Tirsi, A.,Javier, E., et al 2007.HPA axis 
dysregulation and memory impairments in type 2 diabetes. J. Clin. Endocrinol. Metab.92, 2439—2445. 
[42] Rohleder, N., Wolf, J.M., Kirschbaum, C., 2003. Glucocorticoid sensitivity in humans-
interindividual differences and acute stresseffects. Stress 6, 207—222. 
[43] Chan, O., Inouye, K., Akirav, E., Park, E., Riddell, M.C.,Vranic, M., et al 2005. Insulin alone 
increases HPA activity, and diabetes lower speak stress responses. Endocrinology 146, 1382—1390. 
